200 results
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
26 Nov 19
Bio-path Holdings Announces Successful Completion of Safety Testing In Stage 2 of Phase 2 Clinical Trial In Acute Myeloid Leukemia
4:30pm
Exhibit 99.1
BIO-PATH HOLDINGS ANNOUNCES SUCCESSFUL COMPLETION OF SAFETY TESTING IN STAGE 2 OF PHASE 2 CLINICAL TRIAL IN ACUTE MYELOID LEUKEMIA …
Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results
HOUSTON – November 26, 2019 – Bio-Path Holdings, Inc
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
6 Mar 19
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
4:30pm
from Phase 2 Study Demonstrates Meaningful Clinical Improvement with Excellent Patient Safety Profile
Company Provides Clinical Development Plan … and safety of prexigebersen in conjunction with low dose cytarabine (LDAC), a therapeutic regimen well-established in treatment of AML patients who cannot
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
8 Jan 20
Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook
4:30pm
clinical trial.
The first step in the revised strategy involved testing the safety of the combination of prexigebersen and decitabine. In November … 2019, the Company announced successful completion of this safety testing in AML and MDS patients in Stage 2 of the Phase 2 clinical study. The safety
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
13 Dec 21
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
7:40am
Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients
HOUSTON – December 13, 2021 – Bio-Path Holdings, Inc., (NASDAQ … nucleic acid cancer drugs, today announces a poster highlighting the safety and preliminary efficacy data of its Phase 2 study of prexigebersen (BP1001
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
5 Apr 21
Regulation FD Disclosure
4:54pm
Exhibit 99.1
Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax … announced the successful completion of the safety run-in of the Stage 2 of the Phase 2 clinical study of prexigebersen (BP1001), a liposomal Grb2
8-K
EX-99.1
5c8vasji
14 May 21
Bio-Path Holdings Reports First Quarter 2021 Financial Results
7:10am
8-K
EX-99.1
oon5o9ttvfwpauj154nh
19 Nov 20
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
4:30pm
8-K
EX-99.1
yquuufdwc06d1r 1k1m
26 Aug 19
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
9:33pm
8-K
EX-99.1
q1cj9llbf p4i
13 Aug 20
Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia
4:30pm
8-K
EX-99.2
53rt0whk
16 Nov 12
Bio-Path Holdings Reports Third Quarter 2012
12:00am
8-K
EX-99.1
gj8ssbth
6 Mar 20
Bio-path Holdings Reports Full Year 2019 Financial Results
7:10am
8-K
EX-99.1
ac9kk45vl1
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
8-K
EX-99.1
vog3a8
27 Apr 20
Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting
4:31pm
8-K
EX-99.1
yq3g2c9z
27 Oct 21
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
9:04am
8-K
EX-99.1
7xc rgozjx
7 Jun 13
Other Events
12:00am
8-K
EX-99.1
5vn47s4wa639r
21 Nov 19
Bio-path Holdings Announces Clearance of Investigational New Drug Application for BP1002
8:20am
8-K
EX-99.1
lavi58j2ttrmggolr
24 Aug 21
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
8:29am
8-K
EX-99.1
ajvxsde lc8t
11 Mar 22
Bio-path Holdings Reports Full Year 2021 Financial Results
7:30am